<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="55637"><DrugName>lumacaftor</DrugName><DrugNamesKey><Name id="42951000">lumacaftor</Name></DrugNamesKey><DrugSynonyms><Name><Value>cystic fibrosis transmembrane regulator corrector (cystic fibrosis), Vertex/CFFT</Value></Name><Name><Value>CFTR correctors (cystic fibrosis), Vertex/CFFT</Value></Name><Name><Value>VRT-422</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>VRT-325</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>VRT-532</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>lumacaftor</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>VX-809</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>815592-21-3</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>936727-05-8</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="20739">Vertex Pharmaceuticals Inc</CompanyOriginator><CompaniesSecondary><Company id="20739">Vertex Pharmaceuticals Inc</Company><Company id="22534">Cystic Fibrosis Foundation Therapeutics Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="55637" type="Drug"><TargetEntity id="463776" type="siDrug">Lumacaftor</TargetEntity></SourceEntity><SourceEntity id="20739" type="Company"><TargetEntity id="4295908317" type="organizationId">Vertex Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="22534" type="Company"><TargetEntity id="5041981133" type="organizationId">Cystic Fibrosis Foundation Therapeutics Inc</TargetEntity></SourceEntity><SourceEntity id="88" type="ciIndication"><TargetEntity id="E84" type="ICD10"></TargetEntity><TargetEntity id="10011762" type="MEDDRA"></TargetEntity><TargetEntity id="D003550" type="MeSH"></TargetEntity><TargetEntity id="586" type="ORPHANET"></TargetEntity><TargetEntity id="-1447400656" type="omicsDisease"></TargetEntity><TargetEntity id="288" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="10232" type="Action"><TargetEntity id="2088" type="Mechanism">Drugs Acting on CFTR Channels</TargetEntity></SourceEntity><SourceEntity id="PTGT-02413" type="ciTarget"><TargetEntity id="64200535510803" type="siTarget">Cystic fibrosis transmembrane conductance regulator</TargetEntity><TargetEntity id="2652" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsSecondary><Indication id="88">Cystic fibrosis</Indication></IndicationsSecondary><ActionsPrimary><Action id="10232">CFTR modulator</Action></ActionsPrimary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="586">Capsule formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2018-03-30T10:57:39.000Z</LastModificationDate><ChangeDateLast>2018-09-11T00:00:00.000Z</ChangeDateLast><AddedDate>2006-07-03T16:00:54.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="20739" linkType="Company"&gt;Vertex&lt;/ulink&gt;, in collaboration with &lt;ulink linkID="22534" linkType="Company"&gt;Cystic Fibrosis Foundation Therapeutics&lt;/ulink&gt; (CFFT),  was developing lumacaftor (VX-809; structure shown), the lead from a program of oral correctors of the cystic fibrosis transmembrane regulator (CFTR) trafficking defect, which included VRT-422, VRT-325  and VRT-532, for the potential treatment of cystic fibrosis (CF) [&lt;ulink linkID="540048" linkType="Reference"&gt;540048&lt;/ulink&gt;], [&lt;ulink linkID="644829" linkType="Reference"&gt;644829&lt;/ulink&gt;], [&lt;ulink linkID="540048" linkType="Reference"&gt;540048&lt;/ulink&gt;]. In March 2009, a phase IIa trial began  [&lt;ulink linkID="994737" linkType="Reference"&gt;994737&lt;/ulink&gt;], [&lt;ulink linkID="995015" linkType="Reference"&gt;995015&lt;/ulink&gt;]; in February 2010, preliminary data were reported [&lt;ulink linkID="1072833" linkType="Reference"&gt;1072833&lt;/ulink&gt;]. However, development of lumacaftor is presumed to have been discontinued in favor of the  fixed-dose combination of &lt;ulink linkID="83569" linkType="Drug"&gt;lumacaftor + ivacaftor&lt;/ulink&gt; for the same indication.  &lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;By February 2015, the EU composition of matter patent had been granted and was due to expire in 2026. At that time, the US composition of matter patent application was pending and would expire in 2026. EU and US patents were subject to potential patent life extensions [&lt;ulink linkID="1642874" linkType="Reference"&gt;1642874&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;By September 2012, lumacaftor had received Fast Track and Orphan drug status [&lt;ulink linkID="1326766" linkType="Reference"&gt;1326766&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In June 2016, clinical data from a Â retrospective analysis of randomized phase III study (TRAFFIC) were presented at the 39th ECFC in Basel, Switzerland. Patients in (n = 889) were received lumacaftor (600 mg, qd or 400 mg, bid) + ivacaftor (250 mg, bid) or placebo. Statistically significant reductions in calprotectin, CRP, IgG, and IL-8 were observed in addition to significant improvement in ppFEV1 with lumacaftor + ivacaftor treatment compared with placebo [&lt;ulink linkID="1778756" linkType="Reference"&gt;1778756&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2013, a double-blind, randomized, parallel-assigned, phase III trial (&lt;ulink linkID="152738" linkType="Protocol"&gt;NCT01931839&lt;/ulink&gt;; VX12-809-105) to evaluate the safety and efficacy of lumacaftor in subjects (expected n = 1200) with cystic fibrosis was initiated in the US, Australia, Austria, Belgium, Canada, Czech Republic, Denmark, France, Germany, Ireland, Italy, Netherlands, Spain, Sweden and the UK. At that time, the trial was expected to complete in March 2016 [&lt;ulink linkID="1722749" linkType="Reference"&gt;1722749&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2013, a double-blind, randomized, placebo-controlled, parallel-assigned, phase III trial (&lt;ulink linkID="114889" linkType="Protocol"&gt;NCT01807949&lt;/ulink&gt;; VX12-809-104; TRANSPORT) to evaluate the safety and efficacy of lumacaftor in combination with &lt;ulink linkID="50417" linkType="Drug"&gt;ivacaftor&lt;/ulink&gt; was initiated in subjects (n = 563) with CF homozygous for the F508del CFTR mutation was initiated in the US, Australia, Austria, Belgium, Canada, Denmark, France, Germany, Spain and the UK. In April 2014, the trial was completed [&lt;ulink linkID="1693283" linkType="Reference"&gt;1693283&lt;/ulink&gt;]. In June 2016, clinical data were presented at the 39th ECFC in Basel, Switzerland. Statistically significant reductions in calprotectin, CRP, IgG, and IL-8 were observed in addition to significant improvement in ppFEV1 with lumacaftor + ivacaftor treatment compared with placebo [&lt;ulink linkID="1778756" linkType="Reference"&gt;1778756&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In October 2008, the company was planning a 28-day, phase IIa trial [&lt;ulink linkID="956585" linkType="Reference"&gt;956585&lt;/ulink&gt;], [&lt;ulink linkID="982641" linkType="Reference"&gt;982641&lt;/ulink&gt;]. In March 2009, Vertex started patients screening in the phase IIa trial (&lt;ulink linkID="49388" linkType="Protocol"&gt;NCT00865904&lt;/ulink&gt;; VX08-809-101). The North American and European, randomized, double-blind, placebo-controlled, parallel-design, 28-day, multiple-dose trial would assess one of four dose levels (25, 50, 100 or 200 mg)  of daily  lumacaftor capsules in 90 patients homozygous for the F508del CFTR mutation. The primary endpoints were safety and tolerability, and the secondary endpoints included pharmacokinetics, pharmacodynamics and the effect on CFTR function [&lt;ulink linkID="994737" linkType="Reference"&gt;994737&lt;/ulink&gt;], [&lt;ulink linkID="995015" linkType="Reference"&gt;995015&lt;/ulink&gt;]. By October 2009, enrollment had been completed [&lt;ulink linkID="1052205" linkType="Reference"&gt;1052205&lt;/ulink&gt;]. By January 2010, the trial had been completed [&lt;ulink linkID="1067607" linkType="Reference"&gt;1067607&lt;/ulink&gt;]. In February 2010, preliminary data were reported. lumacaftor was safe and well tolerated at all four doses tested. In the 100- and 200-mg once-daily dose groups, activity of the CFTR protein was increased during dosing, as reflected by a significant decrease in sweat chloride. This response was dose-dependent. At that time, further analyses of secondary endpoints were ongoing [&lt;ulink linkID="1072833" linkType="Reference"&gt;1072833&lt;/ulink&gt;]. In March 2011, similar data were presented at 112th Annual Meeting of the ASCPT in Dallas, TX [&lt;ulink linkID="1172841" linkType="Reference"&gt;1172841&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 2008, dosing had been completed in a single dose phase I trial that was evaluating  the pharmacokinetics and safety of a solid dosage form in healthy volunteers. Based on the results, the company began  a single dose pharmacokinetic and safety trial  in CF patients   [&lt;ulink linkID="956585" linkType="Reference"&gt;956585&lt;/ulink&gt;]. In March 2012, data were presented from 26 subjects at the 113th Annual Meeting of the ASCPT in National Harbor, MD.  The mean Cmax, AUC(0 to infinity) and half-life values of VX-809 (200 mg po capsule)  in fasting condition in healthy subjects were 6.97 microg/ml, 208 microg.h/ml and 26 h, respectively, and in CF patients (n = 7) were 9.88 microg/ml, 189 microg.h/ml and 23 h, respectively; in both healthy subjects (fasting condition) and CF patients, the median Tmax values were 4 h. In fed condition, the mean Cmax, AUC(0 to infinity), and half-life values of VX-809 in healthy subjects were 9.09 microg/ml, 240 microg.h/ml and 26 h, respectively, and in CF patients were 7.82 microg/ml, 217 microg.h/ml, and 23 h, rvespectively; the median Tmax values in HS and CF patients were 6 and 6.1 h, respectively. In either group, the bioavailability of VX-809 was minimally affected by food. VX-809 was well tolerated [&lt;ulink linkID="1269871" linkType="Reference"&gt;1269871&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2007, a phase I trial was planned [&lt;ulink linkID="845344" linkType="Reference"&gt;845344&lt;/ulink&gt;]. By January 2008, the phase Ia trial had begun, to evaluate single and multiple doses of lumacaftor in healthy volunteers [&lt;ulink linkID="865541" linkType="Reference"&gt;865541&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;Â In March 2018, in vitro data were presented at 255th ACS National Meeting and Exposition in New Orleans, LA. Clinical combination of lumacaftor and ivacaftor was found to be generally well tolerated for up to 120 weeks in cystic fibrosis treatment [&lt;ulink linkID="2013212" linkType="Reference"&gt;2013212&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2016, preclinical data were presented at the 251st ACS meeting in San Diego, CA. VX-809 had EC50 values of 0.10 and 0.08 microM in FRT and HBE cells, respectively [&lt;ulink linkID="1741172" linkType="Reference"&gt;1741172&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By September 2007, late-stage lead optimization was ongoing  [&lt;ulink linkID="830119" linkType="Reference"&gt;830119&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2006, data were published showing that VRT-422, VRT-325, and VRT-532 corrected the function of delta-F508 mutated CFTR forms in murine fibroblasts human bronchial epithelia [&lt;ulink linkID="797668" linkType="Reference"&gt;797668&lt;/ulink&gt;]. Similar results were presented in September 2007, at SMR's Emerging Therapies in Respiratory Diseases meeting in Cambridge, UK. VRT-325 was shown to be effective in producing the desired transport of CFTR, and pulse-chase studies also indicated that the drug enhances the residency time of CFTR in the cell membrane, suggesting that it may  correct the misfolding of the protein [&lt;ulink linkID="830119" linkType="Reference"&gt;830119&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By May 2004, compounds from the series had been shown to improve CFTR function in bronchial epithelial cells isolated from CF patients [&lt;ulink linkID="540048" linkType="Reference"&gt;540048&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;Vertex holds worldwide development and commercialization rights. Lumacaftor was discovered under a research collaboration with Cystic Fibrosis Foundation Therapeutics signed in May 2000. In May 2004, Vertex  expanded its collaboration with Cystic Fibrosis Foundation Therapeutics; under the new agreement, Vertex was to receive $21 million for its late-stage CF drug discovery program to optimize and select drug candidates. CFFT was also to issue a milestone payment to Vertex for advancement of the first compound into clinical trials. Vertex would retain the right to develop and commercialize any compounds discovered  [&lt;ulink linkID="540048" linkType="Reference"&gt;540048&lt;/ulink&gt;], [&lt;ulink linkID="1172705" linkType="Reference"&gt;1172705&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2012, the EMA's Pediatric Committee adopted a positive opinion on a pediatric investigation plan (PIP)  [&lt;ulink linkID="1294798" linkType="Reference"&gt;1294798&lt;/ulink&gt;]. In September 2013, the Pediatric Committee adopted a positive opinion to modificationsÂ of the agreed pediatric investigation plan [&lt;ulink linkID="1481266" linkType="Reference"&gt;1481266&lt;/ulink&gt;]. In June 2015, The PDCO agreed further changes to the PIP [&lt;ulink linkID="1674993" linkType="Reference"&gt;1674993&lt;/ulink&gt;]. &lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="20739">Vertex Pharmaceuticals Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="88">Cystic fibrosis</Indication><StatusDate>2015-03-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20739">Vertex Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="88">Cystic fibrosis</Indication><StatusDate>2015-03-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20739">Vertex Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="88">Cystic fibrosis</Indication><StatusDate>2015-03-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22534">Cystic Fibrosis Foundation Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="88">Cystic fibrosis</Indication><StatusDate>2015-05-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="22534">Cystic Fibrosis Foundation Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="88">Cystic fibrosis</Indication><StatusDate>2004-05-24T00:00:00.000Z</StatusDate><Source id="540048" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20739">Vertex Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="88">Cystic fibrosis</Indication><StatusDate>2009-03-25T00:00:00.000Z</StatusDate><Source id="994737" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20739">Vertex Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="88">Cystic fibrosis</Indication><StatusDate>2009-03-25T00:00:00.000Z</StatusDate><Source id="994737" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20739">Vertex Pharmaceuticals Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="88">Cystic fibrosis</Indication><StatusDate>2014-09-22T00:00:00.000Z</StatusDate><Source id="1599336" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20739">Vertex Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="88">Cystic fibrosis</Indication><StatusDate>2004-05-24T00:00:00.000Z</StatusDate><Source id="540048" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20739">Vertex Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="88">Cystic fibrosis</Indication><StatusDate>2008-01-07T00:00:00.000Z</StatusDate><Source id="865541" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="20739">Vertex Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="88">Cystic fibrosis</Indication><AwardedIndication>Treatment of cystic fibrosis (CF)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2012-09-27T00:00:00.000Z</MileStoneDate><Source id="1326766" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="20739">Vertex Pharmaceuticals Inc</OwnerCompany><Country id="AU">Australia</Country><Indication id="88">Cystic fibrosis</Indication><AwardedIndication>In combination with Ivacaftor (VX-770) for the treatment of cystic fibrosis (CF) in patients who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2014-09-22T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="20739">Vertex Pharmaceuticals Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="88">Cystic fibrosis</Indication><AwardedIndication>Treatment of cystic fibrosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate>2012-11-30T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="20739">Vertex Pharmaceuticals Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="88">Cystic fibrosis</Indication><AwardedIndication>Treatment of cystic fibrosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2010-08-04T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="20739">Vertex Pharmaceuticals Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="88">Cystic fibrosis</Indication><AwardedIndication>Treatment of cystic fibrosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2010-05-06T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="20739">Vertex Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="88">Cystic fibrosis</Indication><AwardedIndication>Treatment of cystic fibrosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2010-03-02T00:00:00.000Z</MileStoneDate></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-02413"><Name>CFTR</Name><SwissprotNumbers><Swissprot>P13569</Swissprot><Swissprot>P26361</Swissprot><Swissprot>P26362</Swissprot><Swissprot>P26363</Swissprot><Swissprot>P34158</Swissprot><Swissprot>P35071</Swissprot><Swissprot>Q00552</Swissprot><Swissprot>Q00553</Swissprot><Swissprot>Q00554</Swissprot><Swissprot>Q00555</Swissprot><Swissprot>Q5D1Z7</Swissprot><Swissprot>Q5U820</Swissprot><Swissprot>Q6PQZ2</Swissprot><Swissprot>Q7JII7</Swissprot><Swissprot>Q7JII8</Swissprot><Swissprot>Q9TSP5</Swissprot><Swissprot>Q9TUQ2</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="20739">Vertex Pharmaceuticals Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="22534">Cystic Fibrosis Foundation Therapeutics Inc</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="1">Drug - Discovery/Design</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>Cc1ccc(nc1c2cccc(c2)C(=O)O)NC(=O)C3(CC3)c4ccc5c(c4)OC(O5)(F)F</Smiles><Smiles>CCCn1c(=O)c2ccccc2nc1C(C)N3CCN(CC3)S(=O)(=O)c4ccc(cc4)Br</Smiles><Smiles>Cc1ccc(c(c1)c2cc([nH]n2)c3ccccc3)O</Smiles><Smiles>CC(c1nc2ccccc2c(n1)OC3CCCCC3)N4CCN(CC4)S(=O)(=O)c5ccc(cc5)OC</Smiles></StructureSmiles><Deals><Deal id="121137" title="Vertex and CFFT to discover novel treatments for CF worldwide              "/><Deal id="124216" title="CFFT and Aurora BioSciences to discover cystic fibrosis therapeutics"/></Deals><PatentFamilies><PatentFamily id="1111415" number="WO-2009076142" title="Processes for producing cycloalkylcarboxiamido-pyridine benzoic acids"/><PatentFamily id="1333582" number="WO-2010037066" title="Dosage units of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid"/><PatentFamily id="1629928" number="WO-2007056341" title="Heterocyclic modulators of ATP-binding cassette transporters"/><PatentFamily id="2150761" number="WO-2010108162" title="Process for making modulators of cystic fibrosis transmembrane conductance regulator"/><PatentFamily id="225266" number="WO-2011127241" title="Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof"/><PatentFamily id="2297570" number="WO-2010138484" title="Processes for producing cycloalkylcarboxamido-pyridine benzoic acids"/><PatentFamily id="2476346" number="WO-2011133751" title="Process of producing cycloalkylcarboxamido-indole compounds"/><PatentFamily id="2506649" number="US-08012999" title="Modulators of cftr"/><PatentFamily id="2568506" number="WO-2013112804" title="Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid"/><PatentFamily id="2798705" number="WO-2014144860" title="Correctors acting through MSD1 of CFTR protein"/><PatentFamily id="2823217" number="WO-2014176553" title="Correctors acting through MSD1 of CFTR protein"/><PatentFamily id="2845450" number="WO-2015173551" title="New treatment"/><PatentFamily id="3212018" number="WO-2016103176" title="Novel Î¡Î3Î gamma inhibitor peptide for treatment of respiratory system diseases"/><PatentFamily id="3245257" number="WO-2016115090" title="Compounds, compositions and methods for increasing CFTR activity"/><PatentFamily id="3295186" number="WO-2016129005" title="Thymosin alpha 1 for use in treatment of cystic fibrosis"/><PatentFamily id="3311634" number="WO-2009073757" title="Solid forms of 3-(6-(1-(2,2-Difluorobenzo[d][1,3]-dioxol-5-yl)-cyclopropanecarboxamido)-3-methylpyridin-2-yl)-benzoic acid"/><PatentFamily id="3387435" number="WO-2016151051" title="Use of alginate oligomers and CFTRÂ modulators in the treatment of conditions associated with CFTR dysfunction"/><PatentFamily id="3489244" number="WO-2016207621" title="In vitro production of cholangiocytes"/><PatentFamily id="3533434" number="WO-2017017696" title="Process for the preparation of lumacaftor"/><PatentFamily id="3542065" number="WO-2017025045" title="Novel crystal form of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxole-5-yl)cyclopropane formamido)-3-methylpyridine-2-yl)benzoic acid and preparation method thereof"/><PatentFamily id="3562525" number="WO-2017035662" title="Modifiers of CFTR-directed therapy"/><PatentFamily id="3611449" number="WO-2017056031" title="Process for preparation of lumacaftor"/><PatentFamily id="3611456" number="WO-2017056109" title="Novel forms of lumacaftor and processes for the preparation thereof"/><PatentFamily id="3668530" number="WO-2017085573" title="Amorphous sacubitril-valsartan complex and process for preparation thereof"/><PatentFamily id="3718498" number="WO-2017118915" title="Amorphous and crystalline solid forms of lumacaftor or its complex and preparative processes thereof"/><PatentFamily id="3749380" number="WO-2017133424" title="Preparation method of 1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-cyclopropanecarboxylic acid and intermediate of the same"/><PatentFamily id="3814614" number="WO-2017175161" title="Solid forms of lumacaftor, its salts and processes thereof"/><PatentFamily id="3821476" number="WO-2017181193" title="Methods and compounds for stimulating read-through of premature termination codons"/><PatentFamily id="3834680" number="WO-2017187338" title="Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them"/><PatentFamily id="3834681" number="WO-2017187340" title="Pharmaceutical combination composition comprising complex formulations of ivacaftor and lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them"/><PatentFamily id="3913517" number="WO-2017137900" title="Amorphous lumacaftor and its solid dispersion"/><PatentFamily id="3963601" number="WO-2018037350" title="Solid forms of lumacaftor, process for its preparation and pharmaceutical compositions thereof"/><PatentFamily id="4007747" number="CN-107823643" title="Drug, the target point for preventing or curing Alzheimer's disease and application thereof"/><PatentFamily id="4017748" number="CN-107880011" title="Lumacaftor synthesis method of key intermediate"/><PatentFamily id="4113940" number="US-20180186721" title="Oxidative coupling of aryl boron reagents with sp3-carbon nucleophiles, and ambient decarboxylative arylation of malonate half-esters via oxidative catalysis"/><PatentFamily id="4122283" number="WO-2018127846" title="Process and crystalline forms of lumacaftor"/><PatentFamily id="4200484" number="WO-2018168777" title="Prophylactic or therapeutic agent for cystic fibrosis"/><PatentFamily id="4286606" number="WO-2018217683" title="Methods for treating cystic fibrosis"/><PatentFamily id="4287292" number="JP-2018188474" title="The deuterated cftr potentiator"/><PatentFamily id="4304006" number="WO-2018227049" title="Methods of treatment for cystic fibrosis"/><PatentFamily id="4321737" number="WO-2018237174" title="Cystic fibrosis transmembrane conductance regulator modulators for treating autosomal dominant polycystic kidney disease"/><PatentFamily id="4363082" number="WO-2019018395" title="Methods of treatment for cystic fibrosis"/><PatentFamily id="4381371" number="IN-201721026278" title="Lumacaftor dichloromethane solvate is prepared by dissolving lumacaftor in dichloromethane, heating the solution, and cooling"/><PatentFamily id="4404850" number="WO-2019038718" title="Crystalline forms of lumacaftor"/><PatentFamily id="4475978" number="US-20190112299" title="Crystalline form of lumacaftor"/><PatentFamily id="4479312" number="WO-2019076919" title="Combination treatment for cystic fibrosis"/><PatentFamily id="665019" number="WO-2011008931" title="Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis &amp;amp; related disorders"/><PatentFamily id="863597" number="WO-2004080972" title="Pyrazole modulators of ATP-binding cassette transporters"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>8</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="11">Process (Intermediate)</Type><Count>6</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>14</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="14">Tentative</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>14</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>11</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>8</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Alabama" id="1006257"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Southeast University" id="1008666"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kwansei Gakuin Educational Foundation" id="1010313"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Verona Pharma plc" id="1017335"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="CoNCERT Pharmaceuticals Inc" id="1021896"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Macleods Pharmaceuticals Ltd" id="1030321"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Laurus Labs Pvt Ltd" id="1038399"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="IRCCS San Raffaele" id="1039610"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Proteostasis Therapeutics Inc" id="1041745"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AlgiPharma AS" id="1043999"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Seattle Children's Hospital" id="1049938"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chinese Academy of Medical Sciences &amp; Peking Union Medical College" id="1066199"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Crystal Pharmatech Co Ltd" id="1077753"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kither Biotech Srl" id="1094666"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Suzhou Vigonvita Life Sciences Co Ltd" id="1108291"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Suzhou WSWS Biological Pharmaceutical Co Ltd" id="1111460"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Darholding Kft" id="1113414"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sorbonne Universites" id="1149274"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cipla Ltd" id="15503"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hospital for Sick Children" id="16994"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="INSERM" id="17229"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mylan NV" id="18439"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="US Government" id="20516"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Alberta" id="20525"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Cambridge" id="20550"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Johns Hopkins University" id="20596"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="McGill University" id="20617"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of North Carolina" id="20634"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Toronto" id="20688"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Vertex Pharmaceuticals Inc" id="20739"/><CountAsOwner>15</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>15</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>5</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Turin" id="21709"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Lupin Ltd" id="21932"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Apotex Inc" id="22353"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cystic Fibrosis Foundation Therapeutics Inc" id="22534"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Assistance Publique Hopitaux de Paris" id="23948"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universita Degli Studi Di Perugia" id="24119"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Wellcome Trust Sanger Institute" id="24961"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sun Pharmaceutical Industries Ltd" id="27561"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Glenmark Pharmaceuticals Ltd" id="29326"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dr Reddy's Laboratories Ltd" id="29387"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Brooklyn ImmunoTherapeutics LLC" id="30720"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universita Degli Studi Di Roma &quot;Tor Vergata&quot;" id="31129"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>